The ADMIRE Network organized a themed issue of the British Journal of Pharmacology entitled

Emerging Fields for Therapeutic Targeting of the Aldosterone-Mineralocorticoid Receptor Signaling Pathway

Edited by: Achim Lother, Ulrich Wenzel, Frédéric Jaisser

Br J Pharmacol. 2022;179(13):3235-3249.


Zhu Z, Rosenkranz KA, Kusunoki Y, Li C, Klaus M, Gross O, Angelotti ML, Antonelli G, Cirillo L, Romagnani P, Bouteldja N, Sadr AV, Bülow RD, Boor P, Anders HJ. Finerenone Added to RAS/SGLT2 Blockade for Chronic Kidney Disease in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice. J Am Soc Nephrol. 2023, in press

Gallego A, Pérez P. Loss of epidermal glucocorticoid receptor protects against whole body metabolic dysfunction upon chronic corticosterone treatment. Mol Metab. 2023 Jun 24;74:101763.

Kintscher U, Edelmann F. The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2023;22(1):162.

Carceller-Zazo E, Sevilla LM, Pons-Alonso O, Chiner-Oms Á, Amazit L, An Vu T, Vitellius G, Viengchareun S, Comas I, Jaszczyszyn Y, Abella M, Alegre-Martí A, Estébanez-Perpiñá E, Lombès M, Pérez P. The mineralocorticoid receptor modulates timing and location of genomic binding by glucocorticoid receptor in response to synthetic glucocorticoids in keratinocytes. FASEB J. 2023;37(1):e22709

Mamazhakypov A, Lother A. Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research. Front Cardiovasc Med. 2023;10:1118516.


Luettges K, Bode M, Diemer JN, Schwanbeck J, Wirth EK, Klopfleisch R, Kappert K, Thiele A, Ritter D, Foryst-Ludwig A, Kolkhof P, Wenzel UO, Kintscher U. Finerenone Reduces Renal RORγt γδ T Cells and Protects against Cardiorenal Damage. Am J Nephrol. 2022;53(7):552-564.

Bauersachs J, Lother A. Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms. Kidney Int Suppl (2011). 2022;12(1):19-26.